Abstract
To report the first use the intravitreal anti-VEGF brolucizumab for the treatment of macular exudates and edema in a patient with Coats’ disease.
A 9-year-old boy was referred with a decrease in vision in the right eye. Visual acuity was 20/400 OD on presentation, and examination was remarkable for peripheral telangiectasias, exudates, microaneurysms, macular edema, and an inferior exudative retinal detachment. A diagnosis of Stage 3A2 Coats’ disease was made, and the patient was treated with intravitreal bevacizumab as well as peripheral diode laser. However, on follow up, there was persistence of subretinal fluid accompanied by a decrease in visual acuity. The patient was then treated with intravitreal brolucizumab. Post injection visual and anatomical improvements were significant with complete resolution of macular edema within two weeks. Throughout the 5 months of follow up, there has been no re-accumulation of fluid and no further required therapy.
Intravitreal brolucizumab was effective for the treatment of retinal edema and exudates in Coats’ disease.
•Intravitreal brolucizumab may be used in select pediatric patients with positive outcomes.•Patients with Coats' disease may benefit from the efficacy of intravitreal brolucizumab.•Intravitreal brolucizumab combined with laser photocoagulation can be effective for advanced Coats disease.